================================================================================
                    AUDITED FINANCIAL STATEMENTS
                    BIOPHARMA INDUSTRIES LIMITED
                    FOR THE YEAR ENDED MARCH 31, 2025
================================================================================

                    INDEPENDENT AUDITOR'S REPORT

To the Members of BioPharma Industries Limited

Report on the Audit of the Financial Statements

OPINION

We have audited the financial statements of BioPharma Industries Limited
("the Company"), which comprise the Balance Sheet as at March 31, 2025, and
the Statement of Profit and Loss, Statement of Changes in Equity and Statement
of Cash Flows for the year then ended, and notes to the financial statements,
including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair
view of the financial position of the Company as at March 31, 2025, and of
its financial performance and its cash flows for the year then ended in
accordance with the Indian Accounting Standards (Ind AS) and other accounting
principles generally accepted in India.

BASIS FOR OPINION

We conducted our audit in accordance with the Standards on Auditing (SAs)
specified under Section 143(10) of the Companies Act, 2013. Our responsibilities
under those Standards are further described in the Auditor's Responsibilities
for the Audit of the Financial Statements section of our report.

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgment, were
of most significance in our audit of the financial statements:

1. Revenue Recognition
   - Risk: Incorrect timing of revenue recognition for domestic and export sales
   - Audit Response: Tested sales cut-off procedures, verified shipping documents
   - Conclusion: Revenue recognition is appropriate

2. Inventory Valuation
   - Risk: Overstatement of inventory due to obsolescence or valuation errors
   - Audit Response: Observed physical verification, tested NRV calculations
   - Conclusion: Inventory valuation is appropriate

3. Regulatory Compliance Provisions
   - Risk: Inadequate provisions for regulatory matters
   - Audit Response: Reviewed legal opinions, discussed with management
   - Conclusion: Provisions are adequate

                                             For M/s. DEF & Co.
                                             Chartered Accountants
                                             FRN: 012345N

                                             Sd/-
                                             CA Dinesh Shah
                                             Partner
                                             M. No.: 098765

Date: May 25, 2025
Place: Mumbai

================================================================================

                    BALANCE SHEET AS AT MARCH 31, 2025

================================================================================

                                          As at          As at
Particulars                               March 31, 2025 March 31, 2024
                                          (Rs. Lakhs)    (Rs. Lakhs)
================================================================================

I. EQUITY AND LIABILITIES

(1) SHAREHOLDERS' FUNDS
    (a) Share Capital                     2,000.00       2,000.00
    (b) Reserves and Surplus              8,950.00       7,890.00
                                         ----------     ----------
    Total Shareholders' Funds            10,950.00       9,890.00

(2) NON-CURRENT LIABILITIES
    (a) Long-term Borrowings              1,800.00       2,100.00
    (b) Deferred Tax Liabilities (Net)      450.00         420.00
    (c) Long-term Provisions                280.00         260.00
                                         ----------     ----------
    Total Non-Current Liabilities         2,530.00       2,780.00

(3) CURRENT LIABILITIES
    (a) Short-term Borrowings             3,200.00       2,800.00
    (b) Trade Payables
        - MSME                              180.00         150.00
        - Others                          2,850.00       2,450.00
    (c) Other Current Liabilities           980.00         870.00
    (d) Short-term Provisions               520.00         480.00
                                         ----------     ----------
    Total Current Liabilities             7,730.00       6,750.00

                                         ----------     ----------
TOTAL EQUITY AND LIABILITIES             21,210.00      19,420.00
================================================================================

II. ASSETS

(1) NON-CURRENT ASSETS
    (a) Property, Plant and Equipment     6,250.00       5,480.00
    (b) Capital Work-in-Progress          1,950.00         650.00
    (c) Intangible Assets                   180.00         150.00
    (d) Financial Assets
        - Investments                       150.00         150.00
        - Other Financial Assets            120.00         100.00
    (e) Other Non-Current Assets            280.00         250.00
                                         ----------     ----------
    Total Non-Current Assets              8,930.00       6,780.00

(2) CURRENT ASSETS
    (a) Inventories                       7,800.00       7,200.00
    (b) Financial Assets
        - Trade Receivables               5,980.00       5,450.00
        - Cash and Cash Equivalents         420.00         380.00
        - Bank Balances                   1,500.00       1,200.00
        - Other Financial Assets            180.00         150.00
    (c) Other Current Assets                400.00         360.00
                                         ----------     ----------
    Total Current Assets                 12,280.00      12,640.00

                                         ----------     ----------
TOTAL ASSETS                             21,210.00      19,420.00
================================================================================

================================================================================

                    STATEMENT OF PROFIT AND LOSS
                    FOR THE YEAR ENDED MARCH 31, 2025

================================================================================

                                          Year ended     Year ended
Particulars                               March 31, 2025 March 31, 2024
                                          (Rs. Lakhs)    (Rs. Lakhs)
================================================================================

I. REVENUE FROM OPERATIONS

   Sale of Products
   - Domestic Sales                       19,850.00      18,240.00
   - Export Sales                         12,550.00      10,680.00
                                         ----------     ----------
   Gross Sales                            32,400.00      28,920.00

   Less: Discounts and Returns              (650.00)       (520.00)
                                         ----------     ----------
   Net Revenue from Operations            31,750.00      28,400.00

II. OTHER INCOME                             380.00         320.00
                                         ----------     ----------
III. TOTAL INCOME                         32,130.00      28,720.00
================================================================================

IV. EXPENSES

   Cost of Materials Consumed             17,400.00      15,890.00
   Changes in Inventories of FG & WIP       (450.00)       (280.00)
   Employee Benefits Expense               4,250.00       3,980.00
   Finance Costs                             480.00         420.00
   Depreciation and Amortization             820.00         740.00
   Research and Development Expenses         280.00         240.00
   Other Expenses                          6,850.00       6,150.00
                                         ----------     ----------
   Total Expenses                         29,630.00      27,140.00
================================================================================

V. PROFIT BEFORE TAX                       2,500.00       1,580.00

VI. TAX EXPENSE
    (a) Current Tax                          650.00         420.00
    (b) Deferred Tax                          30.00          20.00
                                         ----------     ----------
    Total Tax Expense                        680.00         440.00

VII. PROFIT FOR THE YEAR                   1,820.00       1,140.00
================================================================================

VIII. OTHER COMPREHENSIVE INCOME

    Items that will not be reclassified
    to profit or loss:
    - Remeasurements of defined benefit
      plans                                  (18.00)        (12.00)
    - Income tax relating to above             4.50           3.00
                                         ----------     ----------
    Total Other Comprehensive Income         (13.50)         (9.00)

IX. TOTAL COMPREHENSIVE INCOME             1,806.50       1,131.00
================================================================================

X. EARNINGS PER SHARE (Face value Rs. 10)
   Basic (Rs.)                                9.10           5.70
   Diluted (Rs.)                              9.10           5.70
================================================================================

================================================================================

                    KEY FINANCIAL RATIOS

================================================================================

Ratio                              FY 2024-25    FY 2023-24    Change
--------------------------------------------------------------------------------
Current Ratio                      1.59          1.87          (15.0%)
Debt-Equity Ratio                  0.46          0.50          (8.0%)
Debt Service Coverage Ratio        3.85          3.42          12.6%
Return on Equity (%)               17.7%         12.2%         45.1%
Inventory Turnover Ratio           4.08          3.95          3.3%
Trade Receivables Turnover         5.56          5.45          2.0%
Trade Payables Turnover            5.74          5.89          (2.5%)
Net Capital Turnover Ratio         6.98          6.23          12.0%
Net Profit Margin (%)              5.7%          4.0%          42.5%
Return on Capital Employed (%)     18.2%         13.5%         34.8%

Notes on Significant Changes:
- Return on Equity increased due to higher profitability
- Net Profit Margin improved due to operational efficiencies
- Current Ratio decreased due to increased working capital financing

================================================================================

                    NOTES TO FINANCIAL STATEMENTS

================================================================================

1. CORPORATE INFORMATION

   BioPharma Industries Limited ("the Company") is a public company domiciled
   in India and incorporated under the provisions of the Companies Act. The
   Company is engaged in the manufacture and sale of pharmaceutical formulations.

2. SIGNIFICANT ACCOUNTING POLICIES

   2.1 Basis of Preparation
       The financial statements are prepared in accordance with Indian
       Accounting Standards (Ind AS) notified under Section 133 of the
       Companies Act, 2013.

   2.2 Revenue Recognition
       Revenue is recognized when control of products is transferred to the
       customer at an amount that reflects the consideration expected.

   2.3 Inventories
       Inventories are valued at lower of cost and net realizable value.
       Cost is determined using weighted average method.

   2.4 Property, Plant and Equipment
       PPE is stated at cost less accumulated depreciation and impairment.
       Depreciation is provided on straight-line basis over useful life.

3. PROPERTY, PLANT AND EQUIPMENT (Rs. Lakhs)

   Category                    Gross Block    Depreciation   Net Block
   --------------------------------------------------------------------
   Land                        450.00         -              450.00
   Buildings                   2,850.00       680.00         2,170.00
   Plant and Machinery         4,250.00       1,420.00       2,830.00
   Laboratory Equipment        580.00         210.00         370.00
   Furniture and Fixtures      280.00         120.00         160.00
   Vehicles                    180.00         90.00          90.00
   Office Equipment            320.00         140.00         180.00
   --------------------------------------------------------------------
   Total                       8,910.00       2,660.00       6,250.00

4. INVENTORIES (Rs. Lakhs)

   Category                                   FY 2024-25    FY 2023-24
   --------------------------------------------------------------------
   Raw Materials                              3,250.00      3,050.00
   Packing Materials                          1,180.00      1,080.00
   Work-in-Progress                           850.00        720.00
   Finished Goods                             2,520.00      2,350.00
   --------------------------------------------------------------------
   Total                                      7,800.00      7,200.00

5. TRADE RECEIVABLES (Rs. Lakhs)

   Ageing Analysis:
   Less than 6 months                         5,420.00      4,980.00
   6 months to 1 year                         480.00        390.00
   More than 1 year                           80.00         80.00
   --------------------------------------------------------------------
   Total                                      5,980.00      5,450.00

   Trade receivables are non-interest bearing and generally on 30-90 days
   credit terms.

6. BORROWINGS

   (a) Long-term Borrowings (Rs. Lakhs)
       Term Loan from Bank                    1,800.00      2,100.00
       (Secured by first charge on PPE, repayable in monthly installments,
       interest rate: 9.5% p.a.)

   (b) Short-term Borrowings (Rs. Lakhs)
       Working Capital Loan from Bank         3,200.00      2,800.00
       (Secured by hypothecation of current assets, interest rate: MCLR + 0.75%)

7. CONTINGENT LIABILITIES (Rs. Lakhs)

   (a) Product liability claims pending       5.00          5.00
   (b) Sales tax/GST matters under dispute    12.00         12.00
   (c) Bank guarantees outstanding            85.00         75.00

8. SEGMENT INFORMATION

   The Company operates in a single business segment (pharmaceuticals) and
   two geographical segments (domestic and export).

   Geographical Segments:              FY 2024-25    FY 2023-24
   ------------------------------------------------------------
   Domestic Revenue                    19,200.00     17,720.00
   Export Revenue                      12,550.00     10,680.00
   ------------------------------------------------------------
   Total                               31,750.00     28,400.00

9. RELATED PARTY TRANSACTIONS (Rs. Lakhs)

   (a) Key Managerial Personnel Remuneration
       - Dr. Ramesh Kulkarni (MD)      100.00        92.00
       - Mrs. Sunita Kulkarni (WTD)    72.00         65.00

   (b) Rent paid to Kulkarni Properties LLP
       (Firm in which directors are partners)
                                       36.00         36.00

10. RESEARCH AND DEVELOPMENT EXPENDITURE

    R&D expenditure for the year: Rs. 280 Lakhs (PY: Rs. 240 Lakhs)
    Percentage of revenue: 0.88% (PY: 0.85%)

11. CORPORATE SOCIAL RESPONSIBILITY

    CSR expenditure required: Rs. 29 Lakhs
    CSR expenditure incurred: Rs. 31 Lakhs
    Nature: Healthcare camps, education, environment

12. EVENTS AFTER REPORTING DATE

    No material events after the balance sheet date requiring adjustment
    or disclosure.

================================================================================

                    CASH FLOW STATEMENT (INDIRECT METHOD)
                    FOR THE YEAR ENDED MARCH 31, 2025

================================================================================
                                          (Rs. Lakhs)
================================================================================

A. CASH FLOW FROM OPERATING ACTIVITIES

   Profit before tax                       2,500.00
   Adjustments for:
   - Depreciation                          820.00
   - Finance costs                         480.00
   - Interest income                       (120.00)
                                          ----------
   Operating profit before working
   capital changes                         3,680.00

   Changes in working capital:
   - (Increase) in inventories             (600.00)
   - (Increase) in trade receivables       (530.00)
   - Increase in trade payables            430.00
   - Increase in other liabilities         170.00
                                          ----------
   Cash generated from operations          3,150.00
   - Income tax paid                       (620.00)
                                          ----------
   Net cash from operating activities      2,530.00

B. CASH FLOW FROM INVESTING ACTIVITIES

   - Purchase of PPE and CWIP              (2,890.00)
   - (Increase) in bank deposits           (300.00)
   - Interest received                     120.00
                                          ----------
   Net cash used in investing activities   (3,070.00)

C. CASH FLOW FROM FINANCING ACTIVITIES

   - Proceeds from short-term borrowings   400.00
   - Repayment of long-term borrowings     (300.00)
   - Finance costs paid                    (480.00)
   - Dividend paid (including DDT)         (240.00)
                                          ----------
   Net cash used in financing activities   (620.00)

Net increase/(decrease) in cash            40.00
Cash at beginning of year                  380.00
                                          ----------
Cash at end of year                        420.00
================================================================================

Signed for and on behalf of the Board of Directors

Sd/-                                       Sd/-
Dr. Ramesh Narayan Kulkarni                Mrs. Sunita Ramesh Kulkarni
Managing Director                          Whole-Time Director
DIN: 00123456                              DIN: 00123457

Sd/-                                       Sd/-
Mr. Rajesh Sharma                          Ms. Kavita Patel
Chief Financial Officer                    Company Secretary

Place: Thane
Date: May 25, 2025

================================================================================
                    END OF AUDITED FINANCIAL STATEMENTS
================================================================================
